Accès gratuit
| Numéro |
Med Sci (Paris)
Volume 34, Numéro 1, Janvier 2018
|
|
|---|---|---|
| Page(s) | 12 - 14 | |
| Section | Le Magazine | |
| DOI | https://doi.org/10.1051/medsci/20183401003 | |
| Publié en ligne | 31 janvier 2018 | |
- Calvayrac O, Pradines A, Pons E, et al. Molecular biomarkers for lung adenocarcinoma. Eur Respir J 2017; 49. pii: 1601734. [CrossRef] [PubMed] [Google Scholar]
- Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. LancetOncol 2012; 13 : 239-46. [Google Scholar]
- Cortot AB, Janne PA. Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas. Eur Respir Rev 2014; 23 : 356-66. [CrossRef] [PubMed] [Google Scholar]
- Faber AC, Corcoran RB, Ebi H, et al. BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 2011; 1 : 352-65. [CrossRef] [PubMed] [Google Scholar]
- de Bruin EC, Cowell C, Warne PH, et al. Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov 2014; 4 : 606-19. [CrossRef] [PubMed] [Google Scholar]
- Tricker EM, Xu C, Uddin S, et al. Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR-mutant lung cancer. Cancer Discov 2015; 5 : 960-71. [CrossRef] [PubMed] [Google Scholar]
- Hata AN, Niederst MJ, Archibald HL, et al. Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition. Nat Med 2016; 22 : 262-9. [CrossRef] [PubMed] [Google Scholar]
- Ramirez M, Rajaram S, Steininger RJ, et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nat Commun 2016; 7 : 10690. [CrossRef] [PubMed] [Google Scholar]
- Primeau M, Lamarche-Vane N. Coup d’œil sur les petites GTPases Rho. Med Sci (Paris) 2008; 24 : 15762. [Google Scholar]
- Mazieres J, Antonia T, Daste G, et al. Loss of RhoB expression in human lung cancer progression. Clin Cancer Res 2004; 10 : 2742-50. [CrossRef] [PubMed] [Google Scholar]
- Bousquet E, Calvayrac O, Mazieres J, et al. RhoB loss induces Rac1-dependent mesenchymal cell invasion in lung cells through PP2A inhibition. Oncogene 2016; 35 : 1760-9. [Google Scholar]
- Calvayrac O, Pradines A, Raymond-Letron I, et al. RhoB determines tumor aggressiveness in a murine EGFRL858R-induced adenocarcinoma model and is a potential prognostic biomarker for Lepidic lung cancer. Clin Cancer Res 2014; 20 : 6541-50. [CrossRef] [PubMed] [Google Scholar]
- Calvayrac O, Mazieres J, Figarol S, et al. The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism. EMBO Mol Med 2017; 9 : 238-50. [CrossRef] [PubMed] [Google Scholar]
Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.
Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.
Le chargement des statistiques peut être long.